Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Incyte Corp

INCY ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: BUY

Last Close

$120.16

▼ -0.30%

Market Cap $24.36B · Vol 284.44K

Key Metrics

P/E Ratio

15.31

FWD: 17.75

Market Cap

$24.36B

Large Cap

Div Yield

N/A

EPS Growth

-47.46%

YoY

RSI (14)

52.05

Momentum

Beta

0.76

vs Market

52W High

$132.58

9.37% below

52W Low

$81.09

48.18% above

Volume

284.44K

Avg 655.93K

P/B

3.79

Price-to-book

ROE

31.70%

Return on equity

Free Float

98.02%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Incyte Corp (INCY) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INCY pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.33%

+4.60%

+23.08%

+18.85%

YTD

+21.66%

+39.46%

+83.70%

+63.55%

Financials & Valuation

TTM · Annual

Total Revenue	$5.14B
Net Income	$1.29B
Revenue Growth (YoY)	+37.72%
Gross Margin	92.76%
Operating Margin	26.12%
Net Profit Margin	25.03%
ROE	31.70%
ROA · ROIC	26.84% · 29.66%

P/E Ratio	15.31
Forward P/E (FY1)	17.75
PEG Ratio	0.00
P/S	3.86
P/B	3.79
P/FCF	14.91
EPS Growth	-47.46%
Outstanding Shares	202.70M

Technical Indicators

50-Day SMA	$113.85
200-Day SMA	$102.85
RSI (14)	52.05
Beta	0.76
52-Week High	$132.58
52-Week Low	$81.09

Volume Today	284.44K
Avg Daily Volume (30D)	655.93K
Relative Volume	0.43x
Volatility (10D)	16.06
Volatility (30D)	33.90
Free Float	98.02%

Analyst Consensus

BUY

Current Price $120.16

Mean Target $125.49

52W Low$81.09 52W High$132.58

Current

Target

$81.09 $132.58

Current Analyst target

+4.43% upside potential · 26 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S8Q6N2

ISINUS45337C1027

CountryUnited States of America

Sub-IndustryBiopharmaceuticals

Earnings DateOct 26, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% CSL.AX CSL Ltd -0.74% BIIB Biogen Inc -0.39%

Company Profile

Incyte Corporation is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of therapeutics. The Company operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise is comprised of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. The Company manages business activities on a consolidated basis through the development and commercialization of oncology and dermatology products.